首页> 外文期刊>Molecules >Qingxuan Jiangya Decoction Reverses Vascular Remodeling by Inducing Vascular Smooth Muscle Cell Apoptosis in Spontaneously Hypertensive Rats
【24h】

Qingxuan Jiangya Decoction Reverses Vascular Remodeling by Inducing Vascular Smooth Muscle Cell Apoptosis in Spontaneously Hypertensive Rats

机译:清宣降压汤通过诱导自发性高血压大鼠血管平滑肌细胞凋亡逆转血管重塑

获取原文
           

摘要

Qingxuan Jiangya Decoction (QXJYD), a traditional Chinese medicine formula prescribed by academician Ke-ji Chen, has been used in China to clinically treat hypertension for decades of years. However, the molecular mechanisms of its action remain largely unknown. In this study, we examined the therapeutic efficacy of QXJYD against elevated systolic blood pressure in the spontaneously hypertensive rat (SHR) model, and investigated the underlying molecular mechanisms. We found that oral administration of QXJYD significantly reduced the elevation of systolic blood pressure in SHR but had no effect on body weight change. Additionally, QXJYD treatment significantly decreased the media thickness and ratio of media thickness/lumen diameter in the carotid arteries of SHR. Moreover, QXJYD remarkably promoted apoptosis of vascular smooth muscle cells and reduced the expression of anti-apoptotic B-cell leukemia/lymphoma 2. Furthermore, QXJYD significantly decreased the plasma Angiotensin II level in SHR. Collectively, our findings suggest that reversing vascular remodeling via inducing VSMC apoptosis could be one of the mechanisms whereby QXJYD treats hypertension.
机译:清宣降压汤(QXJYD)是陈可继院士开出的中药配方,在中国已被用于临床治疗高血压数十年。但是,其作用的分子机制仍然是未知的。在这项研究中,我们检查了QXJYD对自发性高血压大鼠(SHR)模型中收缩压升高的治疗效果,并研究了其潜在的分子机制。我们发现口服QXJYD可以显着降低SHR的收缩压升高,但对体重变化没有影响。此外,QXJYD治疗显着降低了SHR颈动脉的介质厚度和介质厚度/管腔直径的比率。此外,QXJYD显着促进了血管平滑肌细胞的凋亡,并降低了抗凋亡B细胞白血病/淋巴瘤2的表达。此外,QXJYD显着降低了SHR中的血浆血管紧张素II水平。总的来说,我们的发现表明通过诱导VSMC凋亡逆转血管重塑可能是QXJYD治疗高血压的机制之一。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号